Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
4,992,318
-
Total 13F shares
-
101,142,467
-
Share change
-
+6,803,579
-
Total reported value
-
$592,695,970
-
Put/Call ratio
-
95%
-
Price per share
-
$5.86
-
Number of holders
-
149
-
Value change
-
+$39,121,650
-
Number of buys
-
83
-
Number of sells
-
52
Institutional Holders of Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN) as of Q4 2022
As of 31 Dec 2022,
Mersana Therapeutics, Inc. - Common Stock, par value $0.0001 per share (MRSN) was held by
149 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
101,142,467 shares.
The largest 10 holders included
ORBIMED ADVISORS LLC, Bain Capital Life Sciences Investors, LLC, Avoro Capital Advisors LLC, BlackRock Inc., STATE STREET CORP, VANGUARD GROUP INC, Bellevue Group AG, Rock Springs Capital Management LP, Sarissa Capital Management LP, and MILLENNIUM MANAGEMENT LLC.
This page lists
150
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.